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This paper will discuss opportunities for linkages between research in animal agriculture and research directly related to human medicine. 
Results of research in animal agriculture have affected certain aspects of clin-
ical medicine for many years. The application of biotechnology to human and 
veterinary medicine involves many techniques used in reproductive biology 
and applied in animal agriculture. Among these are embryo transfer, gene in-
jection, use of embryonic stem cells for introduction of genes and cloning of 
embryos. Gene transfer in animals is being used to evaluate the value of trans-
genic animals in animal agriculture. Transgenic animals are also being used 
for the study of specific genetic defects. Production of transgenic animals 
has received much attention recently. This technique represents only one ap-
proach which can be used not only to examine questions of interest to the 
biomedical community, but will also help establish linkages between animal 
agriculture, veterinary medicine and human medicine. Naturally occurring 
diseases in livestock must be examined for their value as models for human 
disease. Regulatory proteins normally secreted by the conceptus (embryo/fe- 
tus and associated membranes) may have unique therapeutic value for cer-
tain diseases. In addition, regulatory proteins secreted in significant amounts 
may be associated with normal development of the conceptus, but with vari-
ous disease states in adults. Although it may be useful to create transgenic 
animals as models for specific diseases, we must also focus on naturally oc-
curring diseases affecting animals that are common to humans.
Reproductive biology, in particular the study of pregnancy in livestock, 
provides numerous opportunities to address questions of biology with appli-
cation to both veterinary and human medicine. Pregnancy and associated de-
velopment of the conceptus seems analogous to compressing events of a life-
time into a period of gestation. Because of extremely rapid development of 
the conceptus, basic questions relative to proliferation and differentiation 
of cells, cell-cell interactions and regulation of gene expression can be
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addressed. Results impact our knowledge of wound healing, cancer biology, 
tissue transplantation biology, immunology, developmental^ regulated ex-
pression of genes, endocrine regulation of maternal and fetal-placental ex-
pression of genes, the hematopietic system and so forth. It is not surprising 
that investigators from numerous disciplines have petitioned for the oppor-
tunity to study fetal-placental tissues of humans. Again, understanding nor-
mal events and mechanisms associated with the reproductive process will di-
rectly impact animal agriculture and the biomedical community.
GENE TRANSFER IN HUMAN AND NONHUMAN ANIMALS
It is clear that techniques such as embryo transfer, gene injection, cloning of 
embryos and related technologies have always been done first in animals so 
that proven methods can later be applied to human and veterinary medicine. 
Gene transfer in animals is now being evaluated critically in a number of spe-
cies and with a number of genes. The problems laboratories face in attempt-
ing to produce transgenic animals include poor expression, lack of expres-
sion or over expression of genes of interest, and in some cases, lack of incor-
poration of injected genes. Documentation of these problems in animals and 
development of technologies to overcome them must be through animal ex-
perimentation before these techniques become useful to clinical medicine. In 
some cases, tissue specific expression is essential. This is also being studied 
extensively in animals in which expression of genes are being restricted to the 
mammary gland and the gene products are being harvested from milk. These 
technologies will eventually impact animal agriculture and medicine, but ex-
perimentation with animals will continue to be central to this research.
ALTERNATIVES TO TRANSGENIC ANIMALS
An alternative to development and use of transgenic animals is the identifica-
tion of animal models which have naturally occurring diseases and/or meta-
bolic disorders that provide natural linkages between animal agriculture and 
the biomedical community. Although rodents or other small laboratory ani-
mals are commonly used, domestic animals should be used as models when-
ever possible so that scientific breakthroughs will impact animal health, hu-
man health and production animal agriculture. For example, sheep are used 
extensively as the animal model for studies of basic questions pertaining to 
pregnancy, perinatology and neonatology in humans in departments of pedi-
atrics and departments of obstetrics and gynecology. Results from such re-
search directly impacts the base of knowledge available to clinicians to im-
prove survival and well-being of neonatal humans and animals. Importantly, 
the same information benefits production animal agriculture.
Trophoblast In terferons
Acquired immunodeficiency syndrome (AIDS) is having devastating effects 
on human health throughout the world. Similar lentivirus-induced diseases
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affect cattle, sheep, horses, goats, primates and cats which makes them excel-
lent animal models for studies of the etiology, prevention and treatment of 
human AIDS. A potential therapeutic drug for AIDS is recombinant leuko-
cyte interferon alpha. The trophoblast of conceptuses of some species (e.g., 
ruminants and humans) produce unique interferons which may be especially 
useful for treatment of AIDS and AIDS-like diseases because the trophoblast 
interferons appear to lack the undesirable toxic side effects of leukocyte 
interferons.
Type I trophoblast interferons (tIFN) of sheep, goats and cows are bio-
chemical signals for maternal recognition of pregnancy which may be useful 
for enhancing fertility in animal agriculture; however, they may also have 
therapeutic value in human and veterinary medicine (Bazer and Johnson, 
1991). The tIFNs have high amino acid sequence homology with both inter-
feron alpha I (IFNa j) and interferon alpha II (IFNa jj) or omega interferon 
(IFNq ) which are produced by white blood cells. The tIFNs produced by 
sheep, cow and goat conceptuses are very similar to each other in structure 
and biological activity. A gene for human tIFN (htIFN) that has 85 to 87 per-
cent homology with sheep tIFN (otIFN) has been cloned from a human pla-
cental cDNA library (Whaley et al., 1991).
The tIFNs have potential therapeutic value because they are interferons 
that inhibit cellular proliferation (Pontzer et al., 1991), exert antiviral effects 
(Pontzeret al., 1991) and regulate the immune system (Newton et al., 1989). 
Evaluation of the potential therapeutic value of tIFNs requires sufficient 
amounts of pure protein for clinical studies. A synthetic gene for sheep tIFN 
is being used in yeast and bacterial expression systems to produce recombi-
nant sheep tIFN (rotIFN) that is identical to natural otIFN in terms of its 
amino acid sequence and biological activities (Ott et al., 1991). The antiviral 
activity of this tIFN is as potent as that of known recombinant leukocyte 
interferons from humans (rhIFN) and cattle (rbIFN), but sheep recombinant 
tIFN does not exert cytotoxic effects characteristic of treatment with rhIFNa  
and rbIFNa  (Pontzer et al., 1991; Bazer et al., 1989). Exposure of human and 
feline peripheral lymphocytes infected with human immunodeficiency virus 
(HIV) and feline immunodeficiency virus (FIV) respectively, to sheep tIFN 
inhibited replication of the viruses, but did not exert cytotoxic effects on the 
infected cells when used at concentrations up to 200,000 antiviral units per 
ml. However, rhIFNa  and rbIFNa  exerted significant cytotoxic effects at only 
1,000 to 5,000 antiviral units per ml.
The tIFNs also have antiproliferative effects on cells that is equivalent to 
or greater than that of rbIFNa  and rhIFNa  (Pontzer et al., 1991) and maybe 
useful in the treatment of cancers. When anticellular activities of sheep tIFN, 
rbIFNa  and rhIFNa  were compared using human amnion (WISH) and 
Madin-Darby bovine kidney (MDBK) cells, all inhibited proliferation of the 
cells. However, sheep tIFN was more effective at lower dosages and, at high
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dosages (50,000 antiviral units per ml), otIFN more effectively blocked cell 
proliferation without adverse effects on cell viability. At the same concentra-
tions of antiviral activity, rbIFNa caused substantial cell death (Pontzer et 
al., 1991; Bazer et al., 1989).
Human patients having steroid-dependent mammary tumors respond 
to treatment with ^-interferons because of increased receptors for progester-
one and decreased receptors for estrogen in tumor cells (DeCicco et al.,
1988). In the pregnant uterus of sheep, tIFN stabilizes receptors for progest-
erone while decreasing receptors for estrogen (Ott et al., 1992). The health 
of many women is affected adversely by estrogen-dependent tumors of the 
mammary glands and reproductive tract. Because estrogen-dependent tu-
mor growth depends on the presence of cellular receptors for estrogen, 
tIFNs have potential therapeutic value because they inhibit synthesis of cel-
lular receptors for estrogen which should prevent estrogen-dependent 
growth of the tumors.
Humans suffering from infection with HIV or diseases such as hairy 
cell leukemia are willing to consider lifelong therapy with rhIFN; however, 
chronic treatment with rhIFN results in development of resistance to the ef-
fects of currently available recombinant rhIFN (Tamm et al., 1987). In addi-
tion, high doses of rhIFN produce intolerable fever and chills, anorexia, 
weight loss and fatigue (Oldham, 1985) and may also cause seizures (Janssen 
et al., 1990). Interferons have both immuno-enhancing and cytotoxic effects; 
therefore, therapeutic doses are chosen which favor the immuno-enhancing 
effects. In contrast, tIFNs act through receptors on the uterine epithelium 
which are in direct contact with the conceptus and are exposed to as much as 
40 million units of antiviral activity per 24 hours without cytotoxic effects. 
These tIFNs have unique “cell friendly” properties which may make them es-
pecially desirable therapeutic agents for use in animal agriculture, veterinary 
medicine and human medicine.
A number of diseases affecting livestock result from infections by lenti- 
viruses of the family Retroviridae. These include, ovine progressive pneumo-
nia virus (OPPV), caprine arthritis-encephalitis virus (CAEV), bovine im-
munodeficiency-like virus (BIV), equine infectious anemia (EIA), feline im-
munodeficiency virus (FIV) and simian immunodeficiency virus (SIV) 
(Haase, 1986). Diseases caused by OPPV, CAEV and BIV, for example, are 
uniquely suited for testing the therapeutic value of tIFNs in the control of 
lentivirus-induced diseases because conceptuses of each of these species se-
crete tIFN. These animal models must be studied to assess the therapeutic 
value of tIFNs in preventing or ameliorating vertical transmission of lenti- 
viruses (i.e., via the placenta), and horizontal transmission (i.e., animal to 
animal), as well as the efficacy of tIFNs in treating infected fetuses and adult 
sheep, goats and cattle.
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Hematopoietic System
Another protein isolated from reproductive tissues of domestic farm animals 
which has potential application to veterinary and human medicine is utero- 
ferrin. Uteroferrin is a purple-colored, progesterone-induced glycoprotein 
secreted by uterine endometrial epithelium of pigs (Bazer et al., 1991). Utero-
ferrin can also be purified from human term-placenta. During pregnancy, 
uteroferrin is transported from uterine secretions into the fetal-placental 
circulation and is targeted to reticuloendothelial cells of the fetal liver, the 
major site of hematopoiesis in fetal pigs. Uteroferrin, from pig uterus is a tar-
trate-resistant acid phosphatase with many properties in common with the 
Type 5 tartrate-resistant acid phosphatase in human placenta, chondrocytes 
of osteoclastic bone tumors, spleens of patients with hairy cell leukemia, as 
well as Gaucher’s and Hodgkin’s diseases (Ketcham et al., 1985). In addition, 
uteroferrin has characteristics similar to those for purple acid phosphatases 
from normal bovine, rat, mouse and pig spleen, as well as bovine milk, bo-
vine uterine secretions, equine uterine secretions and rat bone. Uteroferrin 
from pig uterus and human placenta is a hematopoietic growth factor having 
granulocyte-erythrocyte-monocyte/macrophage-megakaryocyte colony 
forming unit (CFU-GEMM) activity that affects differentiation of primitive 
nonadherent hematopoietic stem cells from pig and human bone marrow 
(Bazer et al., 1991).
Uteroferrin from pig uterine endometrium and human placenta 
(Ketcham, 1988), appears to influence hematopoiesis during fetal life. In 
adult humans, however, the presence of the Type 5 tartrate-resistant acid 
phosphatase, which has high amino acid sequence homology with utero-
ferrin, is indicative of abnormal function of cells associated with hematopoi-
etic tissues (Ketcham et al., 1985) in such diseases as hairy cell leukemia. It is 
not clear why there is such abundant secretion of uteroferrin by pig uterus 
and human term-placenta during the course of a normal pregnancy while the 
apparently identical protein is associated with pathological conditions in 
adults, e.g., hairy cell leukemia. An understanding of this paradoxical situa-
tion requires further studies to determine the precise role of uteroferrin in 
hematopoiesis. Animal agriculture, veterinary medicine and human medi-
cine will benefit from collaborative efforts to understand the role of this pro-
tein in health and disease.
Reproductive Management
Research with farm animals has contributed significantly to the development 
and use of clinical methods to enhance fertility through the use of techniques 
for in vitro fertilization, embryo transfer, embryo culture, endocrine therapy, 
cloning of embryos and cryopreservation of sperm, ova and embryos. These 
techniques are used to enhance fertility in human and nonhuman animals. 
Methods for contraception or reducing fertility are also based, in large part,
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on results of experiments with domestic livestock. Functional sterility is de-
sired by many humans to limit family size and in animals it may be used to 
control growth of populations in general or in a specific geographical area. 
Research continues to develop methods which render one functionally ster-
ile, but are reversible. Progress in development of immunological methods 
for achieving fertility control continue and will impact programs designed 
to offer safe and effective alternatives for regulation of fertility in human and 
nonhuman animals.
DEVELOPMENT OF ANIMAL GENETIC MODELS OF DISEASE
Development of animal models to study human disease often raises ethical 
and/or animal welfare issues. However, these issues must be considered in 
light of the tremendous positive impact disease research has had in the past 
and will undoubtedly provide for the future for both human and nonhuman 
animals. Diseases of humans and animals must be understood if the adverse 
impact of those diseases are to be ameliorated or eliminated. The possibility 
of experimentation with naturally occurring or transgenic animal models ex-
pressing diseases, or metabolic disorders, is essential to the biomedical com-
munity. Otherwise, we could not adequately address issues of health, disease 
and reproductive management that our increasingly global society will pre-
sent during the next century.
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